Suppr超能文献

TP53 p.Arg337His 种系突变在巴西南部的流行率:对年轻乳腺癌患者进行突变检测的进一步证据。

TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients.

机构信息

Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

Laboratório de Medicina Genômica, Centro de Pesquisa Experimental do Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

出版信息

PLoS One. 2018 Dec 31;13(12):e0209934. doi: 10.1371/journal.pone.0209934. eCollection 2018.

Abstract

Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1-1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93-5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios.

摘要

绝经前乳腺癌(BC)是 Li-Fraumeni(LFS)和 Li-Fraumeni 样(LFL)综合征的核心肿瘤,是由 TP53 基因突变引起的种系易感性疾病。在巴西南部和东南部地区,发现了一种特定的 TP53 种系突变 c.1010G>A(p.Arg337His),其人群频率为 0.3%,这是有史以来描述的 TP53 种系变异的最高值。在巴西 BC 患者中,携带者频率可从 0.5%到 8.7%不等。本研究通过基因分型 TP53 c.1010G>A 评估了 2 个 BC 组的携带者频率:1)315 名未选择诊断年龄和家族史(FH)的患者;2)239 名诊断年龄在 46 岁之前且不符合 LFS 或 LFL 的 Chompret 标准的患者。在第 1 组中发现了 1 名携带者(0.3%;95%CI 0.1-1.76%),在第 2 组中发现了 6 名携带者(2.5%;95%CI 0.93-5.39%)。两组之间的频率差异具有统计学意义(p = 0.04)。在第 2 组中观察到的突变携带者频率可能证明对诊断年龄在 46 岁之前且不符合 LFS 或 LFL 的 Chompret 标准的 BC 患者进行突变检测是合理的。在不同年龄段和不同地区的更大样本的 BC 患者中进行进一步的研究,对于在不同情况下提供更明确的 TP53 p.Arg337His 携带者频率是必要的。

相似文献

1
TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients.
PLoS One. 2018 Dec 31;13(12):e0209934. doi: 10.1371/journal.pone.0209934. eCollection 2018.
2
Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.
3
Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
PLoS One. 2021 Sep 16;16(9):e0251639. doi: 10.1371/journal.pone.0251639. eCollection 2021.
4
MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Cancer Genet. 2020 Jan;240:54-58. doi: 10.1016/j.cancergen.2019.11.005. Epub 2019 Nov 20.
6
Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
PLoS One. 2014 Jun 17;9(6):e99893. doi: 10.1371/journal.pone.0099893. eCollection 2014.
7
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
J Steroid Biochem Mol Biol. 2019 Jun;190:250-255. doi: 10.1016/j.jsbmb.2019.04.011. Epub 2019 Apr 8.
8
TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Fam Cancer. 2017 Apr;16(2):243-248. doi: 10.1007/s10689-016-9935-z.
10
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Cancer Lett. 2007 Jan 8;245(1-2):96-102. doi: 10.1016/j.canlet.2005.12.039. Epub 2006 Feb 21.

引用本文的文献

1
Epidemiological profile of breast cancer in a reference center in the north region of Brazil.
Rev Bras Ginecol Obstet. 2025 May 4;47. doi: 10.61622/rbgo/2025rbgo27. eCollection 2025.
2
Ancestry and self-reported race in Brazilian breast cancer women.
Rev Assoc Med Bras (1992). 2023 Oct 30;69(12):e20230767. doi: 10.1590/1806-9282.20230767. eCollection 2023.
4
Hereditary cancer syndromes.
World J Clin Oncol. 2023 Feb 24;14(2):40-68. doi: 10.5306/wjco.v14.i2.40.
5
Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by p.R337H Carriers.
Front Oncol. 2022 Mar 16;12:836937. doi: 10.3389/fonc.2022.836937. eCollection 2022.
6
Impact of a submaximal mono-articular exercise on the skeletal muscle function of patients with sickle cell disease.
Eur J Appl Physiol. 2021 Sep;121(9):2459-2470. doi: 10.1007/s00421-021-04716-2. Epub 2021 May 22.
7
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
PLoS One. 2021 Feb 19;16(2):e0247363. doi: 10.1371/journal.pone.0247363. eCollection 2021.

本文引用的文献

3
Breast cancer risk factors.
Prz Menopauzalny. 2015 Sep;14(3):196-202. doi: 10.5114/pm.2015.54346. Epub 2015 Sep 30.
4
Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
J Clin Oncol. 2015 Oct 1;33(28):3092-5. doi: 10.1200/JCO.2015.60.8596. Epub 2015 Aug 17.
7
Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
PLoS One. 2014 Jun 17;9(6):e99893. doi: 10.1371/journal.pone.0099893. eCollection 2014.
9
Unravelling mechanisms of p53-mediated tumour suppression.
Nat Rev Cancer. 2014 May;14(5):359-70. doi: 10.1038/nrc3711. Epub 2014 Apr 17.
10
TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families.
Hered Cancer Clin Pract. 2014 Mar 13;12(1):8. doi: 10.1186/1897-4287-12-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验